Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Costentin

Showing results (231-240 of 244) with videos related to

Pageof 25
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 1, 1995
The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approachesN Griffon, P Sokoloff, J Diaz, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1994
In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypesC Labbé-Jullié, I Dubuc, A Brouard, et al.
L'Encephale|July 4, 2008
[Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature]M-A Crocq, V Camus, B Millet, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1995
Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodentsF Sautel, N Griffon, P Sokoloff, et al.
International Clinical Psychopharmacology|September 1, 1995
The D3 receptor and its relevance in psychiatryJ C Schwartz, N Griffon, J Diaz, et al.
Clinical Neuropharmacology|January 1, 1992
Functional and pharmacological aspects of central neuropeptidergic transmission mediated by neurotensin and neuromedin nP Kitabgi, F De Nadai, C Labbe-Jullie, et al.
Neuropeptides|February 1, 1985
Kelatorphan: a full inhibitor of enkephalin degrading enzymes. Biochemical and pharmacological properties, regional distribution of enkephalinase in rat brain by use of a tritiated derivativeG Waksman, R Bouboutou, P Chaillet, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1987
Enantiomers of thiorphan and acetorphan: correlation between enkephalinase inhibition, protection of endogenous enkephalins and behavioral effectsB Giros, C Gros, J C Schwartz, et al.
European Journal of Biochemistry|December 26, 2001
Synthesis, conformational analysis and biological activity of cyclic analogs of the octadecaneuropeptide ODN. Design of a potent endozepine antagonistJ Leprince, H Oulyadi, D Vaudry, et al.
Biochemical Society Transactions|February 1, 1996
Functional models for the dopamine D3 receptorN Griffon, F Sautel, C Pilon, et al.
Pageof 25

Showing results (231-240 of 244) with videos related to

Sort By:
Pageof 25
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 1, 1995
The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approachesN Griffon, P Sokoloff, J Diaz, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1994
In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypesC Labbé-Jullié, I Dubuc, A Brouard, et al.
L'Encephale|July 4, 2008
[Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature]M-A Crocq, V Camus, B Millet, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1995
Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodentsF Sautel, N Griffon, P Sokoloff, et al.
International Clinical Psychopharmacology|September 1, 1995
The D3 receptor and its relevance in psychiatryJ C Schwartz, N Griffon, J Diaz, et al.
Clinical Neuropharmacology|January 1, 1992
Functional and pharmacological aspects of central neuropeptidergic transmission mediated by neurotensin and neuromedin nP Kitabgi, F De Nadai, C Labbe-Jullie, et al.
Neuropeptides|February 1, 1985
Kelatorphan: a full inhibitor of enkephalin degrading enzymes. Biochemical and pharmacological properties, regional distribution of enkephalinase in rat brain by use of a tritiated derivativeG Waksman, R Bouboutou, P Chaillet, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1987
Enantiomers of thiorphan and acetorphan: correlation between enkephalinase inhibition, protection of endogenous enkephalins and behavioral effectsB Giros, C Gros, J C Schwartz, et al.
European Journal of Biochemistry|December 26, 2001
Synthesis, conformational analysis and biological activity of cyclic analogs of the octadecaneuropeptide ODN. Design of a potent endozepine antagonistJ Leprince, H Oulyadi, D Vaudry, et al.
Biochemical Society Transactions|February 1, 1996
Functional models for the dopamine D3 receptorN Griffon, F Sautel, C Pilon, et al.
Pageof 25